Pharmacology, Biochemistry, and Behavior
July 2003
Justin R Eckler, Jean Chang-Fong, R A Rabin et al.
The present investigation was undertaken to test the hypothesis that known metabolites of the phenylethylamine hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) are pharmacologically active. This hypothesis was tested by evaluating the ability of racemic DOM metabolites 2-O-desmethyl DOM (2-DM-DOM) and 5-O-desmethyl DOM (5-DM-DOM) to substitute for the stimulus properties of...
Journal of Neural Transmission
July 1, 2003
H B Lebsanft, Andreas Mayerhofer, Karl-A Kovar et al.
3,4-Methylenedioxymethamphetamine (MDMA) has recently been hypothesized to be effective against the symptoms of Parkinson's disease. Therefore we tested the effects of MDMA-derivatives in the rotational behavioural model. Male Sprague Dawley rats were lesioned unilaterally with 6-hydroxydopamine at the medial forebrain bundle. MDMA was administered at doses of 2.5, 5.0 and 10.0 mg/kg, its...
Molecular Pharmacology
June 2003
Vincent Setola, Sandra J Hufeisen, K Jane Grande-Allen et al.
Recent findings have implicated the 5-hydroxytryptamine 2B (5-HT2B) serotonin receptor in mediating the heart valve fibroplasia [valvular heart disease (VHD)] and primary pulmonary hypertension observed in patients taking the now-banned appetite suppressant fenfluramine (Pondimin, Redux). Via large-scale, random screening of a portion of the receptorome, we have discovered that the amphetamine...
Pharmacology, Biochemistry, and Behavior
May 2003
Justin R Eckler, R A Rabin, Jerrold C Winter
Nefazodone is presently marketed as an antidepressant that inhibits both serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine reuptake while antagonizing pirenpirone (5-HT2) receptors. This 5-HT receptor type is believed to play a prominent role in the underlying mechanism of action of serotonergic hallucinogens. Antidepressant medications now represent the most commonly prescribed...
Pharmacology & Therapeutics
April 2003
J C Cole, Harry Sumnall
Ecstasy is the second most widely abused illegal drug in Europe. Ecstasy is the colloquial name for 3,4-methylenedioxymethamphetamine (MDMA), but not all Ecstasy tablets contain MDMA. When taken in hot, crowded environments, Ecstasy/MDMA users have developed acute complications that have had fatal consequences. Epidemiological evidence indicates that adverse reactions to Ecstasy/MDMA...
Psychopharmacology
February 2003
Randy L Smith, Robert J. Barrett, Elaine Sanders‐bush
The drug discrimination procedure has proven to be a valuable tool for studying the mechanism of action of psychoactive drugs. Recently, mice with targeted gene mutations have been developed that may also prove useful in evaluating the role of specific receptors in mediating the actions of drugs. We were interested in studying the effects of hallucinogens in genetically modified mice using the...
CNS Spectrums
February 1, 2003
Alan B Douglass
Does narcolepsy, a neurological disease, need to be considered when diagnosing major mental illness? Clinicians have reported cases of narcolepsy with prominent hypnagogic hallucinations that were mistakenly diagnosed as schizophrenia. In some bipolar disorder patients with narcolepsy, the HH resulted in their receiving a more severe diagnosis (ie, bipolar disorder with psychotic features or...
Cognitive Neuropsychiatry
2003
Konstantine K. Zakzanis, Donald A. Young, Zachariah Campbell
22 citations
Introduction: Quantitative evidence has begun to emerge where human studies suggest that repeated recreational use of +/- 3,4-methylenedioxy-methamphetamine (MDMA or "Ecstasy") produces lasting impairments in explicit memory. The purpose of this investigation was to further explore the nature and pattern of component memory processes in abstinent MDMA users. Methods: Accordingly, 15 MDMA users...
Pharmacology, Biochemistry, and Behavior
December 2002
Jerrold C Winter, Justin R Eckler, Mireille M Doat et al.
Previous reports from our laboratory have provided evidence that acute, i.e., concurrent, treatment with selective serotonin reuptake inhibitors (SSRIs) augments the stimulus effects of indoleamine and phenethylamine hallucinogens in the rat. In the present investigation, the acute effects of fluoxetine and citalopram on stimulus control induced by (-)-2,5-dimethoxy-4-methylamphetamine (DOM)...
Brain Research
November 22, 2002
Suzanne Colbron, Mark Jones, Stephany M Biello
3,4-Methylenedioxymethamphetamine (MDMA or 'Ecstasy') is a widely used recreational drug that damages serotonin 5-HT neurons in animals and possibly humans. Published literature has shown that the serotonergic system is involved in photic and non-photic phase shifting of the circadian clock, which is located in the suprachiasmatic nuclei. Despite the dense innervation of the circadian system by...